Weekly roundup: Big ideas, bold moves, and the future of biotech
Last week, Optimum hosted its 17th Annual Healthcare Investor Conference 2025. Held in the heart of London, the event brought together a powerhouse of industry leaders, investors, innovators, and communicators to exchange ideas, explore the market outlook, and tackle the pressing questions facing the life sciences sector.
If you missed the day, or just want to relive it, Optimum TV has got you covered! We are releasing a series of panel summary videos, so you can hear the learnings from the day straight from the panellists themselves.
Featuring: Nick Bastin of Optimum, Renee Aguiar-Lucander of Hansa Biopharma, Hakan Goker of M Ventures, Premal Pajwani of PRP Advisory, and Peter Van de Sande of Synaffix.
📺 Who’s listening? How to tailor the narrative for maximum punch
Featuring: Philip Brainin of Sound Bioventures, Amanda Gett-Chaperot of Kurma Partners, Bonnie van Wilgenburg of Monograph Capital, Mary Clark of Optimum, and Raymond Barlow, SynOx Therapeutics.
📺Thriving in tough times: scaling smart and staying strong
Featuring: Kristin-Anne Rutter of Cambridge University Health Partners, Nicole Mather of IBM, Nick Keher of Oxford Nanopore Technologies, and Jeremy Skillington of Poolbeg Pharma.
Stayed tuned for more Optimum TV Conference specials next week…
Ona Therapeutics appoints oncology drug development veteran Dr. Antoine Yver as Chair to accelerate ADC programs to clinical inflection points
Ona Therapeutics, a global biotech company pioneering first-in-class antibody-drug conjugates (ADCs), announced the appointment of Dr. Antoine Yver, M.D., M.Sc., as Chair of its Board of Directors. Dr Yver has led the development and approval of multiple breakthrough oncology drugs, and this strategic appointment marks a defining step in Ona’s growth as it prepares to advance its lead ADC, ONA-255, into clinical trials for breast cancer treatment in early 2026.
Actithera secures exclusive rights to innovative covalent chemistry technologies from Weizmann Institute for targeted radiopharmaceutical applications
Actithera, a biotechnology company pioneering next-generation radiopharmaceutical therapies, announced an exclusive license agreement with Yeda, the commercial arm of the Weizmann Institute of Science. The agreement covers two patent families of breakthrough covalent chemistry technologies. Actithera will apply these innovations in advancing its proprietary platform for radiopharmaceutical drug discovery and development. This follows the company’s $75.5 million Series A financing secured in July.
Mission Therapeutics raises $13.3 million to progress first-in-class Parkinson’s disease candidate MTX325 through clinical trials
Mission Therapeutics, a Cambridge (UK) based clinical-stage biotech developing first-in-class therapeutics that promote cell and organ health by enhancing mitophagy, announced a $13.3 million raise from its current investors to fully execute its Phase Ib proof-of-mechanism study of MTX325 in patients with Parkinson’s disease. The raise follows the successful completion of Phase Ia studies in healthy volunteers which showed MTX325 to be safe and tolerable, and included PET scans confirming that MTX325 penetrates functional brain tissue.
🔥 Hot topic
While the obesity drugs market is growing fast, the market for cancer drugs shouldn’t be underestimated – and looks set to retain its title as the most valuable segment for some years. Read our latest Hot Topic here.
👥 BIO-Europe Fall
The 31st annual BIO-Europe returns to Vienna, Austria on November 3–5, 2025, where historic coffee houses have long inspired world-changing ideas. BIO-Europe continues this tradition, gathering over 5,700 life science professionals from more than 3,000 companies across 60+ countries and facilitating more than 30,000 one-to-one meetings.
The Optimum Team will be in attendance and we would love to connect with you all there. Reach out to marketing@optimumcomms.com to schedule a meeting!
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
